Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2721-2726

  Sakao, Seiichiro ^a   Tanabe, Nobuhiro ^a   Kasahara, Yasunori ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Endothelin receptor antagonists (ERAs); Phosphodi esterase type 5 (PDE5) inhibitors; Pulmonary arterial hypertension (PAH)

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; TADALAFIL;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; JAPANESE; KAPLAN MEIER METHOD; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; EPOPROSTENOL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; RECEPTORS, ENDOTHELIN; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84867758325     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.8162     Document Type: Article

References (14)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Car-diol 43: 13S-24S, 2004.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary ar-terial hypertension. N Engl J Med 351: 1425-1436, 2004.
3. Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compel-ling evidence of long-term outcomes in pulmonary arterial hyper-tension? A clinical perspective. J Am Coll Cardiol 57: 1053-1061, 2011.
4. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54: S78-S84, 2009.
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vaso-constrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
6. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endo-thelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43: 62S-67S, 2004.
7. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmo-nary Arterial Hypertension (SUPER) Study Group. Sildenafil cit-rate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157, 2005.
8. Galie N, Humbert M, Vachiery JL, et al. Arterial Pulmonary Hy-pertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in pa-tients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39: 1496-1502, 2002.
9. Barst RJ, McGoon M, McLaughlin V, et al; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41: 2119-2125, 2003.
10. Mubarak KK. A review of prostaglandin analogs in the manage-ment of patients with pulmonary arterial hypertension. Respir Med 104: 9-21, 2010.
11. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S 43-S54, 2009.
12. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hyper-tension: a national prospective study. Ann Intern Med 107: 216-223, 1987.
13. REVEAL registry, Available at http://www.revealregistry.com. Accessed February 24, 2009.
14. Information source: Lung Rx Information obtained from Clinical-Trials.gov. Available at http://clinicaltrials.gov/ct2/home